迷幻藥市場規模、佔有率和成長分析（按來源、類型、藥物、用途、給藥途徑、最終用戶、通路和地區分類）—2026-2033年產業預測

預計到 2024 年，迷幻藥市場規模將達到 30.667 億美元，到 2025 年將成長至 34.7457 億美元，到 2033 年將成長至 94.3498 億美元，在預測期（2026-2033 年）內複合成長率 13.3%。

受人們對精神健康治療日益成長的興趣以及對壓力、焦慮和憂鬱症等問題解決方案的迫切需求的推動，迷幻藥市場正經歷著顯著成長。這些物質為精神疾病的管理提供了不同的替代機制，但療效不一。政府和精神健康組織的舉措正在推動這一成長，而情緒障礙（尤其是在年輕人中）的增加也推動了對創新療法的需求。儘管副作用和監管障礙等挑戰依然存在，但迷幻藥在治療領域的日益普及預示著該行業的良好前景。對這些藥物的持續投資和研發表明其前景光明，隨著精神健康護理的不斷發展，迷幻藥市場已成為相關人員需要重點關注的領域。

迷幻藥市場促進因素

迷幻藥物的受歡迎程度正在迅速飆升，它們被視為治療和康復心理健康問題的潛在方案。迷幻藥物緩解憂鬱症症狀的能力吸引了許多研究人員和科學家的關注，他們正積極探索其治療價值。該領域的持續創新和研究提高了人們對迷幻藥物的接受度和認知度，促使其廣泛應用。這種日益成長的興趣和在各個應用領域取得的成功，顯著推動了各地對迷幻藥物需求的成長，凸顯了這些藥物成為市場主要驅動力的潛力。

對迷幻藥市場的限制

迷幻藥市場的成長可能受到這些物質高昂成本的阻礙。此外，嚴格的監管和合規要求也構成進一步的障礙，可能影響市場擴張。這些財務和監管方面的挑戰可能會造成迷幻藥普及和上市速度放緩的環境，最終抑制整體市場成長。隨著業界努力應對這些複雜的挑戰，高成本和嚴格的法律體制可能會限制這些產品在醫療保健和治療領域中得到更廣泛的接受和應用。

迷幻藥市場的趨勢

迷幻藥市場的一個顯著趨勢是醫院藥局領域的成長，這主要得益於大眾對心理健康問題和迷幻藥治療潛力的日益關注。隨著越來越多的人尋求專業協助，對這些需要醫療專業人員處方才能處方箋的藥物的需求也隨之激增。這種轉變不僅強化了醫院藥局作為通路的作用，也促使它們更參與某些疾病的治療管理。因此，迷幻藥與醫療保健系統的日益融合，預示著治療模式和藥房運作正在發生重大變革。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 監管環境
• 專利分析
• 案例研究
• 客戶和購買標準分析

全球迷幻藥市場規模（按來源和複合年成長率分類）（2026-2033 年）

• 合成
• 自然的

全球迷幻藥市場規模（按類型和複合年成長率分類）（2026-2033 年）

• 共濟劑
• 分離性藥物
• 其他

全球迷幻藥市場規模（按藥物類型和複合年成長率分類）（2026-2033 年）

• γ-羥基丁酸（GHB）
• 氯胺酮
• 裸蓋菇素
• 麥角酸二乙醯胺（LSD）
• 3,4-亞甲基安非他命（MDMA）
• 其他

全球迷幻藥市場規模（按應用及複合年成長率分類）（2026-2033 年）

• 嗜睡症
• 難治性憂鬱症
• 重度憂鬱症
• 鴉片類成癮
• 創傷後壓力症候群（PTSD）
• 其他

全球迷幻藥市場規模（依給藥途徑及複合年成長率分類）（2026-2033 年）

• 口服
• 吸入
• 注射

全球迷幻藥市場規模（依最終用戶分類）及複合年成長率（2026-2033 年）

• 醫院
• 專科診所
• 居家醫療
• 其他

全球迷幻藥市場規模（依分銷管道分類）及複合年成長率（2026-2033 年）

• 醫院藥房
• 零售藥房
• 網路藥房

全球迷幻藥市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2021-2023年營收年比比較

主要企業簡介

• Pfizer Inc.（USA）
• Johnson & Johnson（USA）
• AbbVie Inc.（USA）
• Jazz Pharmaceuticals（Ireland）
• Compass Pathways（UK）
• MindMed（Canada）
• Atai Life Sciences（Germany）
• Cybin Corp.（Canada）
• Field Trip Health（Canada）
• GH Research（Ireland）
• Beckley Psytech（UK）
• Seelos Therapeutics（USA）
• Numinus Wellness Inc.（Canada）
• Delix Therapeutics（USA）
• Mydecine Innovations Group（Canada）
• Revive Therapeutics Ltd.（Canada）
• Entheon Biomedical（Canada）
• Mind Cure Health Inc.（Canada）
• PsyBio Therapeutics（USA）
• Tryp Therapeutics（USA）

結論與建議

Psychedelic Drugs Market size was valued at USD 3066.7 Million in 2024 and is poised to grow from USD 3474.57 Million in 2025 to USD 9434.98 Million by 2033, growing at a CAGR of 13.3% during the forecast period (2026-2033).

The market for psychedelic drugs is experiencing significant growth driven by heightened awareness of mental health treatment and the urgent need to address issues like stress, anxiety, and depression. These substances offer alternative mechanisms for managing mental conditions, with varying degrees of effectiveness. Initiatives from governments and mental health organizations are fostering this growth, as increased prevalence of mood disorders, notably among youth, creates a greater demand for innovative treatments. Although challenges remain, such as side effects and regulatory hurdles, the expanding acceptance of psychedelics in therapeutic settings bodes well for the industry. Continued investment and research into these drugs suggest a promising future, making the psychedelic drug market a key area for stakeholders to monitor amid ongoing developments in mental health care.

Top-down and bottom-up approaches were used to estimate and validate the size of the Psychedelic Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Psychedelic Drugs Market Segments Analysis

Global Psychedelic Drugs Market is segmented by source, type, drug, application, route of administration, end-user, distribution channel and region. Based on source, the market is segmented into synthetic and natural. Based on type, the market is segmented into empathogens, dissociatives and others. Based on drug, the market is segmented into gamma-hydroxybutyric acid (GHB), ketamine, psilocybin, lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA) and others. Based on application, the market is segmented into narcolepsy, treatment-resistant depression, major depressive disorder, opiate addiction, post-traumatic stress disorder (PTSD) and others. Based on route of administration, the market is segmented into oral, inhalation and injectable. Based on end-user, the market is segmented into hospitals, specialty clinics, homecare and others. Based on distribution channel, the market is segmented into hospital pharmacy, retail pharmacy and online pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Psychedelic Drugs Market

The popularity of psychedelic drugs has surged as they emerge as potential solutions for mental health treatment and healing. Their ability to alleviate conditions like depression has captured the interest of researchers and scientists who are exploring their therapeutic value. With ongoing innovation and research in this field, there is a growing acceptance and recognition of psychedelic medications, driving their use and adoption. This escalating interest and success observed in various applications have significantly contributed to the increasing demand for psychedelic substances across various regions, highlighting the potential of these drugs as major drivers in the market.

Restraints in the Psychedelic Drugs Market

The growth of the psychedelic drugs market is likely to be hindered by the substantial expenses associated with these substances. Additionally, the presence of rigid regulations and compliance requirements presents further obstacles that may affect market expansion. These financial and regulatory challenges create an environment that could slow the adoption and accessibility of psychedelic drugs, ultimately restraining overall market growth. As the industry navigates these complexities, the combination of high costs and stringent legislative frameworks could limit the potential for wider acceptance and integration of these products in healthcare and therapeutic settings.

Market Trends of the Psychedelic Drugs Market

The psychedelic drugs market is witnessing a notable trend towards the growth of the hospital pharmacy segment, fueled by heightened public awareness surrounding mental health issues and the therapeutic potential of psychedelics. As more individuals seek professional help, the demand for these substances, which necessitate prescriptions from medical practitioners, is surging. This shift is not only enhancing the role of hospital pharmacies as distribution channels but also catalyzing their involvement in the management of specific medical conditions. Consequently, this increasing integration of psychedelics into healthcare frameworks underscores a significant transformation in treatment paradigms and pharmacy operations.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Patent Analysis
• Case Studies
• Customer & Buying Criteria Analysis

Global Psychedelic Drugs Market Size by Source & CAGR (2026-2033)

• Market Overview
• Synthetic
• Natural

Global Psychedelic Drugs Market Size by Type & CAGR (2026-2033)

• Market Overview
• Empathogens
• Dissociatives
• Others

Global Psychedelic Drugs Market Size by Drug & CAGR (2026-2033)

• Market Overview
• Gamma-Hydroxybutyric Acid (GHB)
• Ketamine
• Psilocybin
• Lysergic Acid Diethylamide (LSD)
• 3,4-Methylenedioxymethamphetamine (MDMA)
• Others

Global Psychedelic Drugs Market Size by Application & CAGR (2026-2033)

• Market Overview
• Narcolepsy
• Treatment-Resistant Depression
• Major Depressive Disorder
• Opiate Addiction
• Post-Traumatic Stress Disorder (PTSD)
• Others

Global Psychedelic Drugs Market Size by Route Of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Inhalation
• Injectable

Global Psychedelic Drugs Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Clinics
• Homecare
• Others

Global Psychedelic Drugs Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Global Psychedelic Drugs Market Size & CAGR (2026-2033)

• North America (Source, Type, Drug, Application, Route of Administration, End-User, Distribution Channel)
  • USA
  • Canada
• Europe (Source, Type, Drug, Application, Route of Administration, End-User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Source, Type, Drug, Application, Route of Administration, End-User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Source, Type, Drug, Application, Route of Administration, End-User, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Source, Type, Drug, Application, Route of Administration, End-User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jazz Pharmaceuticals (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Compass Pathways (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MindMed (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Atai Life Sciences (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cybin Corp. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Field Trip Health (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GH Research (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beckley Psytech (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Seelos Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Numinus Wellness Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Delix Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mydecine Innovations Group (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Revive Therapeutics Ltd. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Entheon Biomedical (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mind Cure Health Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PsyBio Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tryp Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations